Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#571 Safety and Efficacy of Peptide Receptor Radionuclide Therapy after Liver Transplantation in Metastatic Neuroendocrine Tumors

Introduction: Liver transplantation is an important option for patients of neuroendocrine tumors (NET) with metastases limited to the liver. Peptide receptor radionuclide therapy (PRRNT) is effective in the management of metastatic NET.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Kulkarni H, Kaemmerer D, Hoersch D, Hommann M, Baum R,

Keywords: liver transplantation, peptide receptor radionuclide therapy,

#567 Efficacy of Combined Peptide Receptor Radionuclide Therapy and Radiofrequency Ablation for the Management of Hepatic Metastases of Neuroendocrine Tumors

Introduction: Hepatic metastases significantly affect the overall prognosis and quality of life in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NET). Radiofrequency ablation (RFA) is one of the important local ablative strategies for hepatic metastases. Peptide receptor radionuclide therapy (PRRNT) is a well-established therapeutic modality for metastatic NET.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Kulkarni H, Kaemmerer D, Petrovich A, Hoersch D, Hommann M,

Keywords: Peptide receptor radionuclide therapy, radiofrequency ablation,

#563 Role of Ga-68 Somatostatin Receptor PET/CT in the Assessment of Response to Radiofrequency Ablation in Hepatic Metastases of Neuroendocrine Tumors

Introduction: Patients with gastroenteropancreatic neuroendocrine tumors (GEP-NET) present frequently with hepatic metastases. Radiofrequency ablation (RFA) is an important local ablative treatment for hepatic metastases.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Kulkarni H, Kaemmerer D, Petrovich A, Hoersch D, Baum R,

Keywords: Somatostatin Receptor PET/CT, radiofrequency ablation, hepatic metastases,

#334 Everolimus + Octreotide LAR v. Placebo + Octreotide LAR in Patients With Advanced NET: Results of a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Trial (RADIANT-2)

Introduction: Everolimus, an oral inhibitor of mTOR, demonstrated promising antitumor activity in patients with NET as a single agent and in combination with octreotide LAR in two phase 2 studies.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Pavel M, Peeters M, Höersch D, Van Cutsem E, Öberg K,

Keywords: mTOR, everolimus, octreotide LAR, neuroendocrine tumor,

#242 Ga-68 SMS-R PET/CT in the Detection of Unknown Primary Neuroendocrine Tumor- Single Centre Result in 124 Patients

Introduction: Ga-68 Somatostatin-Receptor PET/CT (R-PET/CT) has been reported to be superior to In-111 octreoscan in the detection of unknown primary of neuroendocrine tumors (CUP-NET) (EJNMMI 2010 Jan;37(1):67-77)

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Prasad V, Hommann M, Settmacher U, Kaemmerer D, Hoersch D,

Keywords: CUP NET, Ga-68 SMS-R PET/CT,